Putting metabolic side effects into perspective: Risks versus benefits of atypical antipsychotics

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 27, 2001, Pages 35-39

  Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

COGNITION; DEPRESSION; DIABETES MELLITUS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; METABOLIC DISORDER; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; ENERGY METABOLISM; HUMANS; HYPERTRIGLYCERIDEMIA; RISK ASSESSMENT; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0035685064     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Causes of the excess mortality of schizophrenia
2. Non-compliance: Or how many aunts has Matilda?
3. Predictors of outcome in schizophrenia
4. Compliance with antipsychotic treatment
5. Tolerability of atypical antipsychotics
6. Obesity as a risk factor of antipsychotic noncompliance
7. Antipsychotic-induced weight gain: A comprehensive research synthesis
8. Novel antipsychotics: Comparison of weight gain liabilities
9. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment
10. Effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis
11. Evaluating the effects of antipsychotics on cognition in schizophrenia
12. Cognitive dysfunction in schizophrenia: A new set of tools for the assessment of cognition and drug effects
13. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: Results from a double-blind study
14. Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptics
15. Risperidone, negative symptoms and cognitive deficit in schizophrenia: An open study
16. Effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
17. Executive function in schizophrenia
18. Effects of clozapine on cognitive function in schizophrenia
19. Cognitive efficacy of atypical antipsychotics in schizophrenia
20. Effect of risperidone on cognition in patients with schizophrenia
21. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
22. Role of cognition in vocational functioning in schizophrenia
23. Discriminant cognitive factors in responder and nonresponder patients with schizophrenia
24. Cognitive dysfunction in schizophrenia and its importance to outcome: The place of atypical antipsychotics in treatment
25. Memory impairment in schizophrenia: Perspectives from psychopathology and pharmacotherapy
26. Depression, demoralization and control over psychotic illness: A comparison of depressed and nondepressed patients with chronic psychosis
27. Depression in chronic schizophrenia
28. Clozapine for the treatment of agitated-depressed patients with cognitive impairment: A report of 3 cases
29. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression
30. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome: A functional approach
31. Adding risperidone to selective serotonin reuptake inhibitor improved chronic depression
32. Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, parkinsonian side effects, and neuroendocrine response
33. Double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia
34. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
35. Schizophrenics kill themselves too: Review of risk factors for suicide
36. Excess mortality of schizophrenia: A meta-analysis
37. Mortality in current and former users of clozapine
38. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine
39. Clozapine-induced weight gain predicts improvement in psychopathology
40. Clozapine-induced weight gain: Prevalence and clinical relevance
41. Weight gain among schizophrenic patients treated with clozapine
42. Differential effect of clozapine on weight: A controlled study
43. Weight gain among patients on clozapine
44. Clozapine and weight gain
45. Weight gain induced by clozapine
46. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A 5-year naturalistic study